Skip to content

Role of Abbreviated MRI in Follow-up of Hepatocellular Carcinoma .

Role of Abbreviated MRI in Follow-up of Hepatocellular Carcinoma Following Locoregional Treatment.

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06168357
Enrollment
55
Registered
2023-12-13
Start date
2024-01-31
Completion date
2027-09-30
Last updated
2023-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Brief summary

Role of ADC value and DWI in abbreviated MRI compared to post-contrast CT in follow-up of HCC after TACE.

Detailed description

Hepatocellular carcinoma (HCC) is the 5th most common cancer in the world and the most common in Egypt . Trans-arterial chemoembolization (TACE) is the treatment recommended for unresectable HCC according to Barcelona clinic liver cancer staging and is widely used . HCC is nourished only by the hepatic artery, so TACE causes ischemia and coagulative necrosis. However; viable neoplastic tissue residual may be seen after TACE. Assessment of post-TACE tumor response is important in determining treatment success and in guiding future therapy . Many studies have assessed the diagnostic performance of multiphasic contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) in diagnosis of HCC with noted higher sensitivity of MRI compared to CT. CT or MRI are recommended for assessment of response after treatment as well . Diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) are functional MRI techniques that detect signal changes in tissues due to water proton motion. The intact membranes of viable tumor cells restrict water diffusion, whereas necrotic tumor cells with disrupted cell membranes exhibit increased water diffusion and which differentiate the biological activity of HCC

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 85 Years

Inclusion criteria

* Patients who underwent TACE for unresectable HCC with patent portal vein based on Doppler, no ascites, and satisfactory liver function. Age between 20-year old and 85-year old

Exclusion criteria

* Estimated GFR less than 60 Previous history of severe allergic reaction to the iodinated contrast agent Patients with claustrophobia who can't undergo MR examination. Patients having cochlear implants or cardiac pacemaker

Design outcomes

Primary

MeasureTime frameDescription
Correlation between tumor enhancement in arterial phase expressed as Hounsfield unit number and ADC value.Baselinecorrelation between tumor enhancement in arterial phase expressed as Hounsfield unit number and ADC value.

Contacts

Primary ContactNour Mokhles Farah, Resident doctor
Nmokhles492@gmail.com01212872901
Backup ContactMostafa Ahmed Sayed, Lecturer
most.rad@aun.edu.eg01092300511

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026